We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Humana (HUM - Free Report) closed the most recent trading day at $491.74, moving +1.07% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.01%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the health insurer had gained 5.63% over the past month, outpacing the Medical sector's loss of 4.56% and the S&P 500's loss of 4.45% in that time.
Investors will be hoping for strength from Humana as it approaches its next earnings release. In that report, analysts expect Humana to post earnings of $7.14 per share. This would mark year-over-year growth of 3.78%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $25.34 billion, up 11.16% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $28.26 per share and revenue of $102.34 billion. These totals would mark changes of +11.97% and +10.19%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Humana. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Humana is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Humana is holding a Forward P/E ratio of 17.22. Its industry sports an average Forward P/E of 15.77, so we one might conclude that Humana is trading at a premium comparatively.
It is also worth noting that HUM currently has a PEG ratio of 1.25. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HUM's industry had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 79, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
Humana (HUM - Free Report) closed the most recent trading day at $491.74, moving +1.07% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.01%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the health insurer had gained 5.63% over the past month, outpacing the Medical sector's loss of 4.56% and the S&P 500's loss of 4.45% in that time.
Investors will be hoping for strength from Humana as it approaches its next earnings release. In that report, analysts expect Humana to post earnings of $7.14 per share. This would mark year-over-year growth of 3.78%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $25.34 billion, up 11.16% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $28.26 per share and revenue of $102.34 billion. These totals would mark changes of +11.97% and +10.19%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Humana. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Humana is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Humana is holding a Forward P/E ratio of 17.22. Its industry sports an average Forward P/E of 15.77, so we one might conclude that Humana is trading at a premium comparatively.
It is also worth noting that HUM currently has a PEG ratio of 1.25. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HUM's industry had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 79, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUM in the coming trading sessions, be sure to utilize Zacks.com.